ReviewHeart failure clinics2017
Heart Failure with Preserved Ejection Fraction in Older Adults.
Review in Heart failure clinics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 64 citations in OpenAlex.
- Oxygen cost of breathing and its association with dyspnea in older patients with heart failure with preserved ejection fraction and obesity.Journal of applied physiology (Bethesda, Md. : 1985) · 2026Article
- Age-related differences in the intake of heart failure therapy among participants from the MyoVasc study.European geriatric medicine · 2026Observational
- Prognostic Role of Immunonutritional Indices in Elderly Patients with HFpEF: Long-Term Follow-Up of the CONUT, PNI, and CALLy Scores.Journal of clinical medicine · 2026Article
- Cohort Profile: A Descriptive Analysis of Patients Aged 75 Years and Older with Public Health Coverage in Madrid at Baseline, Including a 5-Year Preobservational Period (2015-2019).Journal of clinical medicine · 2026Article
- Improved Survival in Octogenarians With Heart Failure: 15-Year Cohort Study From a National Referral Center.JACC. Advances · 2025Article
- The use of SGLT2 inhibitors in older people: What is important?Aging clinical and experimental research · 2025Review
- Article
- Review
- The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout.Drugs & aging · 2024Review
- 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.Acta Cardiologica Sinica · 2024Article
- Adverse cardiovascular and metabolic perturbations among older women: 'fat-craving' hearts.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- Heart Failure Management Capability and Exacerbation of Heart Failure - A 6-Month Prospective Cohort Study.Circulation reports · 2023Article
- Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators.International journal of molecular sciences · 2022Review
- Transforming growth factor-β in myocardial disease.Nature reviews. Cardiology · 2022Review
- Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models.Circulation research · 2022Review
- Novel biomarkers of inflammation in heart failure with preserved ejection fraction: analysis from a large prospective cohort study.BMC cardiovascular disorders · 2022Article
- Crossroads between Estrogen Loss, Obesity, and Heart Failure with Preserved Ejection Fraction.Arquivos brasileiros de cardiologia · 2021Review
- Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies.ESC heart failure · 2021Review
- Acute heart failure in elderly patients: a review of invasive and non-invasive management.Journal of geriatric cardiology : JGC · 2021Article
- Age-related alterations in cardiac and arterial structure and function in hypertensive women and men.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Most elderly patients, particularly women, who have heart failure, have a preserved ejection fraction. Patients with this syndrome have severe symptoms of exercise intolerance, frequent hospitalizations, and increased mortality. Despite the importance of heart failure with preserved ejection fraction (HFpEF), the understanding of its pathophysiology is incomplete, and optimal treatment remains largely undefined. Unlike the management of HFrEF, there is a paucity of large evidence-based trials demonstrating morbidity and mortality benefit for the treatment of HFpEF. An update is presented on information regarding pathophysiology, diagnosis, management, and future directions in this important and growing disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.